Generally, cationic vector-based intravenous delivery of at a ratio of 4 nitrogen equivalents per DNA phosphate. DNA is hindered by interactions of positively charged comLower levels of transfection were found in the heart, plexes with serum proteins. However, if optimally formuspleen, liver and kidney. Expression was dose-and timelated, cationic vectors can provide reasonable levels of dependent in all tissues examined. In the lung, ␤-galactotransfection in the lung either by intravenous or intrapulsidase staining showed transgene expression in clusters monary routes. We investigated the in vivo transfection of 10 or more pulmonary cells including the alveolar endocapacity of a cationic polymer: linear, 22 kDa polyethylenithelium, squamous and great alveolar epithelial cells (type mine. PEI/DNA complexes were formulated in 5% glucose I and II pneumocytes) and septal cells. These findings indiand delivered into adult mice through the tail vein. Two cate that the complexes pass the capillary barrier in the marker genes were used, ␤-galactosidase and luciferase.
A number of generations of cationic vectors have been synthetised and tested in a variety of in vivo models and some have been taken to clinical trials. Most of these vectors are either monocationic or polycationic lipids, but there has been more recent interest in cationic polymers. Indeed, we showed that the branched cationic polymer polyethylenimine (PEI) can provide high levels of transfection in vivo. [1] [2] [3] In particular the lowest molecular weight preparation then commercially available, the 25 kDa preparation from Aldrich, was shown to be a versatile and efficient vector in the mammalian brain. 2 In a more recent study, 3 we chose to examine the effect of formulation procedures (glucose or saline solutions) on the size and in vivo transfection activity of a mixture of linear polymers with a mean MW of 22 kDa (Exgene 500; Euromedex, Souffleweyersheim, France). We found that the complexes formed in glucose were an order of magnitude smaller than those formed in saline and these complexes provided high levels of gene transfer following dilution into a physiological medium, the cerebrospinal fluid. In the light of these findings we chose to examine the effects of injecting complexes of plasmid DNA formulated with 22 kDa PEI in 5% glucose directly into the blood system and to examine transgene expression in a variety of organs.
PEI-DNA complexes with different ratios of PEI nitro- gen to DNA phosphate (N/P ratio) were prepared in 5% glucose using a CMV-Luc plasmid 4 and the 22 kDa linear PEI. This PEI is synthesised to a degree of polymerisation of 510 units. Earlier experiments carried out with the branched 25 kDa PEI (Aldrich, St Quentin, France) showed this polymer to be toxic, causing death within a few minutes, even when used at low N/P ratios. Similarly, a protocol formulating DNA with 22 kDa PEI in 150 mm NaCl, although not toxic, was not continued as levels of transgene expression were two orders of magnitude lower than those seen when formulating complexes in glucose.
As seen in Figure 1a when complexing CMV-luc with 22 kDa PEI at ratios of 3 to 5 PEI nitrogens per phosphate (N/P) transgene expression was found 24 h later in lungs, heart, spleen, liver, kidney and brain. To analyse the statistical significance of the differences between luciferase expression levels in the various organs and experimental conditions, Student's t test was applied after one-way analysis of variance (ANOVA) with post hoc multiple comparison analysis for independent variables. Differences were considered significant at P Ͻ 0.05. Lung consistently showed the highest levels of expression (the maximum in this experiment being 1.6 × 10 7 ± 7 × 10 6 RLU/mg protein, mean ± s.e.m, n = 5), whereas levels in heart, spleen, liver and kidney were two orders of magnitude lower. The differences between levels of expression in lung and other organs was significant for each PEI/DNA ratio used. The brain showed the lowest detectable expression of the tissues examined (2.4 × 10 3 ± 1.83 × 10 2 RLU/mg protein, mean ± s.e.m, n = 5 at N/P4). An N/P ratio of 4 gave the highest expression in the lungs, levels being more than an order of magnitude higher than with a N/P of 3 (P Ͻ 0.01). However, increasing N/P to 5 ( Figure 1a ) or 6 (data not shown) did not increase transgene expression in the lung (P Ͼ 0.05 for N/P 4 versus N/P 5). Using 125 g DNA with a N/P ratio of 6 was toxic in 50% of the mice injected, so no further investigation of the effect of increasing N/P ratio was carried out. Comparing levels of transgene expression obtained with PEI to those obtained with naked DNA we note that PEI formulation improved transgene expression 10 4 times in the lung, 100-fold in the liver and brain, but only 10-fold in the kidney. Naked DNA gave no detectable signal in the heart.
Varying the amount of DNA injected (from 25 to 125 g) at an optimal N/P ratio of 4 in a constant volume of 5% glucose showed expression to be dose-dependent in each tissue examined (Figure 1b) . Expression was also a function of time (Figure 1c ). High levels of expression were found at the first time-point examined (6 h). The maximal level of expression was maintained in the lungs over the first 24 h, but dropped more rapidly in other tissues.
To determine the precise pattern of expression of exogenous genes after intravenous injection in the tail, we used a plasmid (125 g) containing the coding sequence of ␤-galactosidase (LacZ) under the CMV promoter (Clonetech, Palo Alto, CA, USA). As for the CMVluc experiments a minimum of four animals per group was used. Mice were killed 24 h after injection, sequentially perfused with 5 mg/l heparine in saline, 2% paraformaldehyde, saline and a standard ␤-galactosidase revealing solution (0.8 mg/ml X-gal; Eurogentec, Seraing, Belgium). After perfusion, all the organs were dissected and ␤-galactosidase revelation continued for 48 h by immersion in the X-gal solution at 30°C. After staining, the organs were either dehydrated in alcohol and clarified in benzyl benzoate/benzyl alcohol 5 or embedded in paraffin for histochemistry. After clarification, clusters of labelled cells were found widely distributed throughout the lung respiratory zone (Figures 2a, b and 3a) . No visible ␤-galactosidase activity was found in the lung conducting airways or in other organs. This may be due to the much lower level of gene delivery found in the other tissues (see Figure 1) . Analysis of paraffin sections of stained lungs confirmed the presence of clusters of cells throughout the respiratory zone and the virtual absence of staining in the conducting airways (Figure 2c ). Typically, the staining appeared in groups of 10 or more cells (Figure 2d ) located in the alveolar region and encompassing at least a whole alveolar septum. To confirm that the spatial distribution observed with the ␤-galactosidase construct was similar to that obtained with the luciferase construct used for the kinetic studies, immunocytochemistry was carried out on paraffin sections of lungs of luciferase-injected animals. Polyclonal anti-luciferase antibody (Cortex Biochem, San Leandro, CA, USA) was used at a 1:300 dilution in PBS with 5% fetal calf serum and revealed with a Dako (Glostrup, Denmark) peroxidase ABC kit. Luciferase expression was found in groups of cells throughout the respiratory zone of the lungs with a distribution pattern closely resembling that obtained with histochemical revelation of the ␤-galactosidase gene (compare Figure 2c with e, and d with f).
To obtain greater anatomical information on transgene expression we used a ␤-galactosidase-expressing plasmid with a nuclear localisation signal (nls) to concentrate the enzyme in the nucleus in order to see better morphological detail. Again, using the same protocol of clarification in toto we found transgene expression in clusters of cells in the respiratory zone of the lungs (Figure 3a) . Pulmonary cell types can be characterized by their distinctive morphology. 6 Histology of transduced lungs showed a variety of cell types to be expressing the transgenes. 
Figure 2 Expression of lacZ and luciferase genes in the mouse lung following a single intravenous injection. One hundred and twenty-five g of either pCMV-␤gal or pCMV-luc was injected into the tail vein after complexation with 22 kDa PEI at a N/P ratio of 4 in 500 l 5% glucose. The animals were killed 24 h later, perfused and stained for ␤-galactosidase activity or for luciferase immunoreactivity as described in the text. (a, b) Clarified lung tissue at low (a) and high (b) power. Transgene expression is found in clusters of cells located throughout the respiratory zone of the lung. (c) Paraffin section (10 m) of stained lung counterstained with Papanicolau solution solution to label nuclei. Staining is found in groups of cells including type II pneumocytes. (e, f) Low (e) and high (f) magnifications of pCMV-luciferase-injected lungs stained by immunocytochemistry showing a similar distribution of the transgene as in panels c and d. Magnification a, ×10; b, ×40; c, e, ×100; d, f, ×500.
These included endothelial cells (arrow in Figure 3b , arrowheads in Figure 3c ), type I and type II pneumocytes (white arrows Figure 3b , c) and other septal cells. Controls for this experiment were lungs from animals injected with irrelevant plasmid/PEI or saline alone. Microscopic analysis of sections of lung tissue from controls and DNA/PEI-injected animals revealed no differences in anatomical appearance. No significant histopathological abnormalities were seen in either the whole mounts or in sections from any group.
Taken together, these data provide evidence that when plasmid DNA is formulated with 22 kDa PEI in 5% glucose, high levels of transgene expression can be found in the lung alveolar tissue. These findings corroborate and extend those published in recent months by a number of groups using a variety of cationic lipids. Lung tissue has been transfected by the intravenous route with poly(ethylene glycol)-phospholipid and polyamine conjugates, 7 or by cationic lipid-protamine-DNA complexes McLachlan et al, 12 Gorman et al 13 )
. One report has c b a appeared on the use of the cationic polymer, linear PEI, to transfect rabbit lung tissue by intrapulmonary instillation.
14 Some conclusions can be drawn from the reports on intravenous delivery. First, the lung is the tissue systematically expressing the highest level of transgene activity after intravenous delivery. This is despite the fact that between 50 and 60% of 32 P-labelled plasmid/ cationic lipid complexes injected into the circulation appear to be taken up by the liver. 15 The level of transgene expression in the liver is low though, no doubt because the complexes are phagocytosed by scavenger cells (Kupffer cells), an entry route that will involve rapid degradation of the plasmid. Data corroborating this idea come from Liu et al, 10 who found that the lung expressed luciferase at a 1000-fold higher level than liver for the same amount of DNA deposited in the tissue. Second, formulation of complexes will affect both stability and retention of complexes. For instance, when mixing cationic lipids with a neutral lipid, the addition of cholesterol rather than DOPE has proven more effective in in vivo conditions. 10 Similar formulation problems are posed with cationic polymers. Complexes of varying size result when DNA is mixed with different PEIs and in solutions of different ionic strength. Complexes are of small size (Ͻ100 m diameter) when produced with branched 25 kDa in NaCl 16 or with the 22 kDa in glucose. 3 Yet only the 22 kDa complexes prepared in glucose could be used without incurring toxic responses and consistently gave high levels of transfection. Moreover, the distribution of transgene expression resulting from 22 kDa/ DNA/glucose formulation was even and regular throughout the lung tissue. It is reasonable to infer that the performance of the DNA/22 kDa PEI complexes formulated in glucose is related to their small size and stability. Indeed, EM studies show the particles to remain discrete up to 24 h after preparation. 3 This resistance to aggregation shown in glucose (with no ionic strength) is probably due to high repulsion between cationic particles which prevents their collapse. This repulsion will be weakened in physiological conditions and larger complexes will form, and this increasing size will be exacerbated by interaction with charged serum proteins. Unfortunately, usual biophysical measurements cannot be used to verify these hypotheses about changing size in physiological conditions, as plasma contains a great number of small particles having the same size range as vector/ DNA complexes which therefore interfere with measurements. Thus, modifications of particle biophysical characteristics cannot be followed as they are hidden by background noise.
A final point is that linear PEI gives levels of luciferase expression in the lung that are as high as, or higher than, any so far reported in the literature (four orders of magnitude over control levels). Our controls were animals injected with an equivalent amount of naked DNA, whereas the only other report to show a similar four orders of magnitude increase was that of Liu et al, 10 who used uninjected animals as controls. Using the same basis of comparison, uninjected animals, PEI vectorisation provides levels of transgene expression five orders of magnitude over background. This result is bolstered by our ␤-galactosidase expression data, obtained with two different constructs, having cytoplasmic and nuclear localisation directed proteins. In both cases, the lung was seen to express the transgene strongly with no histological abnormality.
In conclusion, we show that, if used in adequate conditions, low molecular weight preparations of PEI can be used to introduce genes, via the intravenous route, into a number of organs in vivo. In particular, the lungs are a major target for genes introduced by this route with complexes reaching cells beyond the capillary barrier. Moreover, and most importantly, no toxicity is seen. Future studies will be directed to understanding the factors affecting biodistribution and to examine the possibility of targeting specific organs and cell types with different ligands or antibodies.
Note added in proof
Given the difficulty of comparing results on luciferase expression from one experimental situation to another, we think it important to add that in our luminometer 10 7 RLU are equivalent to 3.5 ng of firefly (Photinus pyralis) luciferase from Boehringer Mannheim. This value is constant whether measured in Promega extraction buffer or in nontransfected tissue extracts prepared in extraction buffer.
